Case number 1:23-cv-00266
Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 27, 2023 | 18 | SO ORDERED re 17 Stipulation and Order Regarding Case Consolidation. Signed by Judge Maryellen Noreika on 6/27/2023. (dlw) (Entered: 06/27/2023) (4) |
| Jun 27, 2023 | N/A | Case associated with lead case: Create association to 1:21-cv-01042-MN. (dlw) (Entered: 06/27/2023) (0) |
| Jun 22, 2023 | 17 | STIPULATION and [Proposed] Order Regarding Case Consolidation by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC. (Phillips, John) (Entered: 06/22/2023) (4) |
| Jun 5, 2023 | 13 | ANSWER to 1 Complaint, Affirmative Defenses by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC.(Phillips, John) Modified on 6/5/2023 (dlw). (Entered: 06/05/2023) (24) |
| Jun 5, 2023 | 14 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Zydus Lifesciences Limited. (Phillips, John) (Entered: 06/05/2023) (2) |
| Jun 5, 2023 | 15 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zydus Lifesciences Limited for Zydus Pharmaceuticals (USA) Inc. filed by Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) (Entered: 06/05/2023) (2) |
| Jun 5, 2023 | 16 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zydus Lifesciences Limited for Zydus Worldwide DMCC filed by Zydus Worldwide DMCC. (Phillips, John) (Entered: 06/05/2023) (2) |
| May 11, 2023 | 10 | [SEALED] STIPULATION and Order by Zydus Healthcare (USA) LLC, Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC. (Bilson, David) (Entered: 05/11/2023) (0) |
| May 11, 2023 | 11 | [SEALED] SO ORDERED re 10 Stipulation and Order Dismissing Defendant Zydus Healthcare (USA) LLC without Prejudice and Amending Caption to Reflect Same. Party Zydus Healthcare (USA) LLC terminated. Attorney David A. Bilson and John C. Phillips, Jr terminated as to this Defendant. Signed by Judge Maryellen Noreika on 5/11/2023. This order has been emailed to local counsel. (dlw) (Entered: 05/11/2023) (0) |
| May 11, 2023 | 12 | REDACTED VERSION of 10 Stipulation by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC. (Bilson, David) (Entered: 05/11/2023) (5) |
| May 4, 2023 | 6 | WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Zydus Pharmaceuticals (USA) Inc. waiver sent on 4/5/2023, answer due 6/5/2023. (Balick, Steven) (Entered: 05/04/2023) (1) |
| May 4, 2023 | 7 | WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Zydus Healthcare (USA) LLC waiver sent on 4/5/2023, answer due 6/5/2023. (Balick, Steven) (Entered: 05/04/2023) (1) |
| May 4, 2023 | 8 | WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Zydus Worldwide DMCC waiver sent on 4/5/2023, answer due 7/5/2023. (Balick, Steven) (Entered: 05/04/2023) (1) |
| May 4, 2023 | 9 | WAIVER OF SERVICE returned executed by Neurocrine Biosciences, Inc.: For Zydus Lifesciences Limited waiver sent on 4/5/2023, answer due 7/5/2023. (Balick, Steven) (Entered: 05/04/2023) (1) |
| Mar 15, 2023 | N/A | Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (nms) (Entered: 03/15/2023) (0) |
| Mar 10, 2023 | 1 | COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Zydus Healthcare (USA) LLC, Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC (Filing fee $ 402, receipt number ADEDC-4087545.) - filed by Neurocrine Biosciences, Inc. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet) (vfm) (Entered: 03/13/2023) (Main Document) (21) |
| Mar 10, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 03/13/2023) (3) |
| Mar 10, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 01/26/2023. Date of Expiration of Patent: 01/11/2031,11/08/2027.Thirty Month Stay Deadline: 10/11/2024. (vfm) (Entered: 03/13/2023) (2) |
| Mar 10, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8 039 627 ;8,357,697. (vfm) (Entered: 03/13/2023) (1) |
| Mar 10, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Neurocrine Biosciences, Inc.. (vfm) (Entered: 03/13/2023) (1) |
| Mar 10, 2023 | N/A | No Summons Issued. (vfm) (Entered: 03/13/2023) (0) |
| Mar 10, 2023 | 1 | COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Zydus Healthcare (USA) LLC, Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC (Filing fee $ 402, receipt number ADEDC-4087545.) - filed by Neurocrine Biosciences, Inc. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet) (vfm) (Entered: 03/13/2023) (Exhibit A-C) (30) |
| Mar 10, 2023 | 1 | COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Zydus Healthcare (USA) LLC, Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc., Zydus Worldwide DMCC (Filing fee $ 402, receipt number ADEDC-4087545.) - filed by Neurocrine Biosciences, Inc. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet) (vfm) (Entered: 03/13/2023) (Civil Cover Sheet) (4) |
